LncRNA DLGAP1-AS2 regulates miR-503/cyclin D1 to promote cell proliferation in non-small cell lung cancer.
Aged
Carcinoma, Non-Small-Cell Lung
/ genetics
Cell Line, Tumor
Cell Proliferation
/ genetics
Cyclin D1
/ genetics
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
/ genetics
Male
MicroRNAs
/ genetics
Middle Aged
Prognosis
RNA, Long Noncoding
/ genetics
SAP90-PSD95 Associated Proteins
/ genetics
Cyclin D1
DLGAP1-AS2
Non-small cell lung cancer
miR-503
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
28 Aug 2021
28 Aug 2021
Historique:
received:
08
10
2020
accepted:
09
08
2021
entrez:
29
8
2021
pubmed:
30
8
2021
medline:
28
12
2021
Statut:
epublish
Résumé
LncRNA DLGAP1-AS2 plays an oncogenic role in glioma, while its role in other cancers is unknown. This study aimed to study the role of DLGAP1-AS2 in non-small cell lung cancer (NSCLC). Expression of DLGAP1-AS2 in NSCLC and paired non-tumor tissues from 64 NSCLC patients and the prognostic value of DLGAP1-AS2 for NSCLC were analyzed by performing a 5-year follow-up study. The interaction between DLGAP1-AS2 and miR-503 was confirmed by dual luciferase reporter assay, and their relationship was explored in NSCLC cells transfected with DLGAP1-AS2 expression vector or miR-503 mimic. The roles of DLGAP1-AS2 and miR-503 in regulating cyclin D1 expression were analyzed by RT-qPCR and Western blot. Cell proliferation was analyzed by CCK-8 assay. DLGAP1-AS2 was upregulated in NSCLC and predicted poor survival. Interaction between DLGAP1-AS2 and miR-503 was confirmed by dual luciferase activity assay. Overexpression experiments showed that DLGAP1-AS2 and miR-503 overexpression failed to significantly affect the expression of each other. Interestingly, DLGAP1-AS2 overexpression upregulated cyclin D1, a target of miR-503, increased cell proliferation and reduced the effects of miR-503 overexpression on cyclin D1 expression and cell proliferation. DLGAP1-AS2 may regulate miR-503/cyclin D1 to promote cell proliferation in NSCLC.
Sections du résumé
BACKGROUND
BACKGROUND
LncRNA DLGAP1-AS2 plays an oncogenic role in glioma, while its role in other cancers is unknown. This study aimed to study the role of DLGAP1-AS2 in non-small cell lung cancer (NSCLC).
METHODS
METHODS
Expression of DLGAP1-AS2 in NSCLC and paired non-tumor tissues from 64 NSCLC patients and the prognostic value of DLGAP1-AS2 for NSCLC were analyzed by performing a 5-year follow-up study. The interaction between DLGAP1-AS2 and miR-503 was confirmed by dual luciferase reporter assay, and their relationship was explored in NSCLC cells transfected with DLGAP1-AS2 expression vector or miR-503 mimic. The roles of DLGAP1-AS2 and miR-503 in regulating cyclin D1 expression were analyzed by RT-qPCR and Western blot. Cell proliferation was analyzed by CCK-8 assay.
RESULTS
RESULTS
DLGAP1-AS2 was upregulated in NSCLC and predicted poor survival. Interaction between DLGAP1-AS2 and miR-503 was confirmed by dual luciferase activity assay. Overexpression experiments showed that DLGAP1-AS2 and miR-503 overexpression failed to significantly affect the expression of each other. Interestingly, DLGAP1-AS2 overexpression upregulated cyclin D1, a target of miR-503, increased cell proliferation and reduced the effects of miR-503 overexpression on cyclin D1 expression and cell proliferation.
CONCLUSIONS
CONCLUSIONS
DLGAP1-AS2 may regulate miR-503/cyclin D1 to promote cell proliferation in NSCLC.
Identifiants
pubmed: 34454450
doi: 10.1186/s12890-021-01633-0
pii: 10.1186/s12890-021-01633-0
pmc: PMC8401159
doi:
Substances chimiques
CCND1 protein, human
0
DLGAP1 protein, human
0
MIRN503 microRNA, human
0
MicroRNAs
0
RNA, Long Noncoding
0
SAP90-PSD95 Associated Proteins
0
Cyclin D1
136601-57-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
277Informations de copyright
© 2021. The Author(s).
Références
Front Oncol. 2017 Sep 01;7:194
pubmed: 28920053
J Thorac Oncol. 2019 Jun;14(6):956
pubmed: 31122558
Cancer. 2017 Dec 15;123 Suppl 24:5079-5099
pubmed: 29205305
Oncogene. 2016 Jul 14;35(28):3647-57
pubmed: 26549028
Geroscience. 2018 Apr;40(2):139-149
pubmed: 29455275
Genomics Proteomics Bioinformatics. 2017 Jun;15(3):208-217
pubmed: 28602785
Tumour Biol. 2015 Nov;36(11):8697-702
pubmed: 26047605
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Cancers (Basel). 2018 Jul 04;10(7):
pubmed: 29973561
Neoplasia. 2018 Aug;20(8):826-837
pubmed: 30015158
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Curr Opin Oncol. 2018 Mar;30(2):69-76
pubmed: 29251665
JAMA Oncol. 2017 Jun 1;3(6):827-831
pubmed: 27892978
J Thorac Oncol. 2016 Jul;11(7):1101-11
pubmed: 27103512
Geroscience. 2019 Oct;41(5):671-679
pubmed: 31104189
Acta Oncol. 2017 Jul;56(7):931-935
pubmed: 28514931
Oncology. 2016;90(4):221-31
pubmed: 26999740
J Pathol. 2011 Jan;223(2):102-15
pubmed: 21125669
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
J Biochem. 2020 Apr 1;167(4):411-418
pubmed: 31899508
FEBS J. 2013 Aug;280(16):3768-79
pubmed: 23731275
Trends Cell Biol. 2018 Apr;28(4):287-301
pubmed: 29274663